OncoMatch/Clinical Trials/NCT06211790
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Is NCT06211790 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anlotinib, Everolimus and Tislelizumab for kidney cancer.
Treatment: Anlotinib, Everolimus and Tislelizumab — Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1 monoclonal antibody
Previously received PD-1/PD-L1 monoclonal antibody
Cannot have received: CTLA-4 antibody
Previously received ... CTLA-4 antibody(cytolytic T lymphocyte-associated antigen)
Cannot have received: immunotherapy
Previously received ... other immunotherapy
Cannot have received: targeted therapy
Previously received targeted therapy
Cannot have received: systemic therapy (radiation, surgery, chemotherapy, immunotherapy, molecular targeted therapy)
Exception: within the four weeks prior to treatment
Patients who have received the following medical interventions in the four weeks prior to treatment: Radiation, surgery, chemotherapy, immunotherapy or molecular targeted therapy for tumors
Lab requirements
Blood counts
HB ≥ 90 g/L; ANC ≥ 1.5 x 10^9/L; PLT ≥ 100 x 10^9/L (no blood transfusion or G-CSF within 14 days)
Kidney function
Serum creatinine ≤ 1.5× ULN or creatinine clearance ≥40 mL/min
Liver function
T-bil ≤1.5×ULN; ALT and AST≤2.5×ULN (≤5×ULN if liver metastasis)
Normal function of major organs ... Blood routine examination criteria ... Serum creatinine (Cr) ≤ 1.5× ULN or creatinine clearance ≥40 mL/min T-bil ≤1.5×ULN ... ALT and AST≤2.5×ULN If liver metastasis, ALT and AST≤5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify